Melissa Randy Gitman

Dr. Melissa Randy Gitman

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Science
Verified
Journal Article
Open access
PDF file
AGAna Silvia Gonzalez-Reiche
Ana Silvia Gonzalez-Reiche
MHMatthew M. Hernandez
Matthew M. Hernandez
MSMitchell J. Sullivan
Mitchell J. Sullivan
BCBrianne Ciferri
Brianne Ciferri
HAHala Alshammary
Hala Alshammary
HBHarm van Bakel
Harm van Bakel
Blighted Gotham: Deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC) during the spring of 2020 have vastly exceeded those reported in China and many other countries. What were the early events that led to such a severe outbreak? Gonzalez-Reiche et al. sampled some of the early patients seeking assistance in February and March of 2020 at the Mount Sinai Health System. Phylogenetic analysis of virus sequences in these people, who were drawn from across NYC, showed that the virus had been independently introduced many times from Europe and elsewhere in the United States. Subsequent clusters of community transmission occurred. The focus of infection in NYC is a marker of the role this city plays as a two-way hub for human movement. Science this issue p. 297

19 July 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SJSamantha Jacobs
Samantha Jacobs
Jonathan L JacobsJonathan L Jacobs
Jonathan L Jacobs
EDEmily K. Dennis
Emily K. Dennis
STSarah Taimur
Sarah Taimur
MRMeenakshi Rana
Meenakshi Rana
VCVishnu Chaturvedi
Vishnu Chaturvedi
Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area.

17 July 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MNMichael D. Nowak
Michael D. Nowak
ESEmilia Mia Sordillo
Emilia Mia Sordillo
MGMelissa Randy Gitman
Melissa Randy Gitman
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi

22 May 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
EPElisabet Pujadas
Elisabet Pujadas
NINnaemeka Ibeh
Nnaemeka Ibeh
MHMatthew M. Hernandez
Matthew M. Hernandez
AWAneta Waluszko
Aneta Waluszko
TSTatyana Sidorenko
Tatyana Sidorenko
MGMelissa Randy Gitman
Melissa Randy Gitman

5 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AWAnia Wajnberg
Ania Wajnberg
MMMayce Mansour
Mayce Mansour
ELEmily Leven
Emily Leven
NBNicole M. Bouvier
Nicole M. Bouvier
GPGopi Patel
Gopi Patel
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The percentage of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can still be detected at considerable time post symptom resolution. Here we investigated both seroconversion and PCR-positivity in a large cohort of convalescent serum donors in New York City. Methods: Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via enzyme-linked immunosorbent assay for presence of anti SARS-CoV-2 spike antibodies. Results: All but three confirmed SARS-CoV-2 patients seroconverted to the SARS-CoV-2 spike while only 37.4% of suspected SARS-CoV-2 patients seroconverted. PCR-positivity was detected up to 28 days from symptom resolution. Conclusions: Here we show that the vast majority of confirmed COVID19 patients seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks post symptom resolution, but it is unclear if this signal represents infectious virus.

8 May 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MHMatthew M. Hernandez
Matthew M. Hernandez
RBRadhika Banu
Radhika Banu
PSParas Shrestha
Paras Shrestha
APArmi Patel
Armi Patel
FCFeng Chen
Feng Chen
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi
As severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infections continue, there is a substantial need for cost‐effective and large‐scale testing that utilizes specimens that can be readily collected from both symptomatic and asymptomatic individuals in various community settings. Although multiple diagnostic methods utilize nasopharyngeal specimens, saliva specimens represent an attractive alternative as they can rapidly and safely be collected from different populations. While saliva has been described as an acceptable clinical matrix for the detection of SARS‐CoV‐2, evaluations of analytic performance across platforms for this specimen type are limited. Here, we used a novel sensitive RT‐PCR/MALDI‐TOF mass spectrometry‐based assay (Agena MassARRAY®) to detect SARS‐CoV‐2 in saliva specimens. The platform demonstrated high diagnostic sensitivity and specificity when compared to matched patient upper respiratory specimens. We also evaluated the analytical sensitivity of the platform and determined the limit of detection of the assay to be 1562.5 copies/ml. Furthermore, across the five individual target components of this assay, there was a range in analytic sensitivities for each target with the N2 target being the most sensitive. Overall, this system also demonstrated comparable performance when compared to the detection of SARS‐CoV‐2 RNA in saliva by the cobas® 6800/8800 SARS‐CoV‐2 real‐time RT‐PCR Test (Roche). Together, we demonstrate that saliva represents an appropriate matrix for SARS‐CoV‐2 detection on the novel Agena system as well as on a conventional real‐time RT‐PCR assay. We conclude that the MassARRAY® system is a sensitive and reliable platform for SARS‐CoV‐2 detection in saliva, offering scalable throughput in a large variety of clinical laboratory settings.